RSCM
MLYS icon

Rock Springs Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Rock Springs Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1M Buy
484,951
+45,200
+10% +$1.24M 0.64% 49
2026
Q1 		$11.9M Buy
439,751
+12,155
+3% +$356K 0.7% 44
2025
Q4 		$15.5M Buy
427,596
+19,283
+5% +$773K 0.8% 39
2025
Q3 		$15.5M Buy
408,313
+83,800
+26% +$1.81M 0.9% 39
2025
Q2 		$4.39M Buy
324,513
+3,700
+1% +$53.6K 0.27% 66
2025
Q1 		$5.09M Buy
+320,813
New +$3.69M 0.29% 64
2024
Q3 		– Sell
-378,932
Closed -$4.43M – 116
2024
Q2 		$4.43M Sell
378,932
-413,683
-52% -$5.21M 0.13% 87
2024
Q1 		$10.2M Sell
792,615
-374,877
-32% -$4.63M 0.26% 77
2023
Q4 		$10M Hold
1,167,492
– – 0.25% 71
2023
Q3 		$11.1M Hold
1,167,492
– – 0.3% 70
2023
Q2 		$19.9M Hold
1,167,492
– – 0.47% 57
2023
Q1 		$18.3M Buy
+1,167,492
New +$19.7M 0.44% 60

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Rock Springs Capital Management's MLYS Position: Q2 2026 in Review

Rock Springs Capital Management increased its Mineralys Therapeutics (MLYS) stake by 10% in Q2 2026, buying an estimated $1.24M and bringing the position to 484,951 shares worth $13.1M. The position accounts for 0.64% of the portfolio, ranked #49.

Rock Springs Capital Management first reported a position in MLYS in Q1 2023 and has held it in 12 quarters since. The position peaked at $19.9M in Q2 2023. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Rock Springs Capital Management held 484,951 shares of Mineralys Therapeutics worth $13.1M as of Q2 2026.
  • Rock Springs Capital Management bought 45,200 Mineralys Therapeutics shares in Q2 2026, an estimated $1.24M.
  • Mineralys Therapeutics made up 0.64% of Rock Springs Capital Management's portfolio in Q2 2026, its #49 holding.
  • Rock Springs Capital Management first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 12 quarters since.
  • Rock Springs Capital Management's Mineralys Therapeutics position peaked at $19.9M in Q2 2023.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.